ME/CFS Research Summaries

Neuroinflammation & Brain Changes

42 min read

Current Takeaway

Central nervous system alterations, impaired neurovascular coupling, and chronic neuroimmune activation represent a key pathological axis in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Post-Acute Sequelae of COVID-19 (PASC). Multimodal imaging—including structural MRI, diffusion tensor and kurtosis imaging (DTI/DKI), functional MRI (fMRI), and task-based EEG—reveals widespread, yet localized, alterations in the post-viral brain. A systematic review of 12 imaging studies confirms that objective white matter tract connectivity changes (42%) and grey matter volume reductions (16%) frequently affect the prefrontal cortex, precentral gyrus, and subcortical regions (thalamus, pallidum, and basal ganglia). Task-based fMRI and EEG demonstrate a central nervous system failure to upregulate motor drive during fatiguing tasks, establishing a biological central neural origin of physical and cognitive fatigability distinct from peripheral muscle fatigue. Furthermore, predictive processing models frame baseline thalamocortical hyperconnectivity with sensorimotor and visual cortices as a reversible thalamic gain control failure that normalizes toward healthy controls following hyperbaric oxygen therapy in clinical responders.

At the cellular and chemokine level, these central alterations are driven by microglial priming, astrogliosis, and prefrontal-hippocampal excitation-inhibition (E/I) imbalance. Preclinical models demonstrate that systemic peripheral inflammation directly exacerbates central cerebral inflammation under hypoxic stress via a CCL5 chemokine-dependent signaling axis, illustrating how peripheral post-viral flares translate into central neuroinflammation. In post-COVID cohorts, [18F]DPA-714 PET/fMRI reveals that high neuroinflammatory activity directly correlates with reduced functional connectivity within visual-peripheral and dorsal-attention networks. Expert syntheses highlight TSPO PET, diffusion MRI, and fluid biomarkers (NfL, GFAP) for patient stratification, while clinical trial protocols actively deploy multimodal MRI to evaluate whether non-invasive therapies can restore hippocampal metabolism and resting-state network connectivity.

Despite these advancements, significant clinical and methodological challenges persist. Group-level neuroimaging and metabolic signatures—such as regional hypoperfusion seen in arterial spin labeling, elevated lactate and glutamate in 7T spectroscopy, and altered gut-brain axis kynurenine metabolites—serve as research observations rather than validated individual diagnostic biomarkers. Crucially, evidence is limited by the heterogeneity of scanning protocols, modest cohort sizes, reliance on cross-sectional designs, and the preliminary nature of conference proceedings and preclinical models. Further large-scale longitudinal validation is required to establish causal pathways linking systemic expression of serotonin-metabolizing enzymes in brainstem endothelial cells, endocrine hyporeactivity, and central nervous system remodeling.

Why This Matters

Characterizing the neurological and neurovascular pathophysiology of post-viral syndromes shifts the clinical understanding from subjective symptom reports to objective, quantifiable biology. Demonstrating that cognitive exhaustion is linked to prefrontal capillary blood flow rigidity, thalamic volume reduction, and altered white matter microstructure provides concrete physical markers that can be evaluated in vivo. Additionally, establishing that visual stimulation triggers cerebral lactate accumulation and cingulate energy depletion proves that cognitive symptoms are rooted in impaired brain energy metabolism.

Identifying specific cellular processes, such as microglial priming, astrocytic dysfunction, and HPA-axis hyporeactivity, points to targeted therapeutic strategies. These include intranasal monoclonal antibodies to recruit regulatory T cells and shift microglia to a restorative state, low-dose hydrocortisone to address the cortisol deficit, or pharmacological agents to rebalance excitatory-inhibitory neurotransmission. Furthermore, establishing a link between haptoglobin phenotypes and post-exertional symptom severity suggests a genetic basis for clinical variability, allowing for personalized, phenotype-informed clinical care and trial stratification.

State of Evidence

  • Established: Post-viral cognitive dysfunction involves objective deficits in attention, executive function, and visual processing speed. Endothelial activation and vascular inflammation are elevated in neurological post-viral cohorts up to a year post-infection. A hyporeactive HPA axis is characterized by decreased salivary, urinary, and hair cortisol levels in patients compared to controls. Widespread white matter microstructural alterations and localized grey matter volume reductions (especially in the prefrontal cortex, precentral gyrus, thalamus, and basal ganglia) are consistently observed at the group level across patient cohorts.
  • Plausible but early: Submaximal exercise induces hyperactivation of the anterior Default Mode Network (medial prefrontal cortex) during resting states. Visual and cognitive tasks trigger abnormal shifts to anaerobic pathways, resulting in elevated visual cortex lactate and reduced cingulate cortex ATP-to-phosphocreatine ratios. Widespread white matter abnormalities, characterized by cerebral edema and cellular infiltration, are detectable using advanced neuroinflammation diffusion MRI. Autopsy tissue reveals functional down-regulation of hypothalamic CRH and vasopressin neurons, and altered microglial states without widespread chronic neuroinflammation. Post-exertional symptom severity is modulated by haptoglobin phenotype (Hp2-1 associated with worse PEM and cognitive deficits). Nicotinic acetylcholine receptor blockade by viral spike proteins impairs cholinergic neurotransmission, which can be restored by nicotine displacement. Intranasal immunomodulation (such as anti-CD3) recruits regulatory T cells to resolve neuroinflammation and restore hippocampal neurogenesis in animal models. Neurocognitive symptoms are associated with reduced within-network connectivity in resting-state cognitive networks (such as default mode, visual-peripheral, and dorsal attention networks), which correlates with high neuroinflammatory activity on [18F]DPA-714 PET in a subset of post-COVID patients. Sensory hypersensitivity in ME/CFS is driven by dysfunction in higher-order cognitive control and attentional processing (characterized by reduced late auditory P300 potential on ERP tasks) rather than early sensory gating deficits. Cognitive dysfunction is driven by functional, modifiable neurovascular and synaptic dysregulation of brain-resident cells (microglial priming, astrocytic dysfunction, and prefrontal-hippocampal E/I imbalance) rather than permanent neurodegenerative damage. Multimodal neuroimaging (fMRI/EEG) demonstrates a central nervous system failure to upregulate motor drive during physical and cognitive tasks, establishing a central neural origin of fatigability distinct from peripheral muscle fatigue. Thalamocortical hyperconnectivity reflects a precision gate control failure mediating sensory overload and cognitive fatigue, which shifts toward healthy control levels in hyperbaric oxygen therapy responders. Systemic peripheral inflammation exacerbates central cerebral inflammation under hypoxic stress via a CCL5 chemokine-dependent microglial activation axis (preclinical model). Controlled physiological hypoxia challenges reveal exhausted thalamic neurometabolic reserve (blunted compensatory lactate response) and abnormal neurovascular coupling in ME/CFS, supporting challenge-based over static imaging designs.
  • Not established: A single, universal neuroimaging or CSF biomarker that reliably diagnoses ME/CFS or Long COVID in clinical settings. Direct causal evidence that glymphatic system waste clearance dysfunction or choroid plexus swelling is the primary driver of cognitive symptoms in human cohorts. The clinical efficacy of low-dose hydrocortisone or neurotransmitter-rebalancing drugs (like memantine or dextromethorphan) in unstratified patient populations. The clinical efficacy of interventions such as acupuncture or hyperbaric oxygen therapy (HBOT) in reversing hippocampal connectivity or metabolic dysfunction in larger, placebo-controlled trials.
  • Key limitations: Many neuroimaging studies feature small, highly heterogeneous cohorts and lack longitudinal follow-up to track whether structural and functional brain changes resolve over time. In vivo measurement of glymphatic flow and choroid plexus perfusion is technically challenging and early-stage. The absence of healthy control groups in cerebrospinal fluid proteomic studies due to ethical lumbar puncture restrictions limits the specificity of identified biomarkers. Animal models of passive antibody transfer, hypoxia models, and intranasal immunotherapy may not fully replicate the chronic, multi-systemic pathobiology of human disease. TSPO-based PET neuroimaging requires complex genotyping to account for binder affinity, limiting its clinical scalability and generalizability. Conference abstracts, clinical trial protocols, and narrative medical reviews represent preliminary, planned, or synthesised work rather than large-scale empirical replication.

Timeline

2021-12-15 - Submaximal exercise provokes default mode network hyperactivation

A functional magnetic resonance imaging (fMRI) study demonstrated that a submaximal exercise challenge induces abnormal resting-state activation in the medial prefrontal cortex, the anterior node of the Default Mode Network (DMN), in patients compared to healthy controls. Prior to exertion, patients exhibited lower overall blood oxygenation level-dependent (BOLD) signal amplitudes, indicating reduced baseline cerebral blood flow. Following exercise, healthy controls showed a decline in BOLD activity in this prefrontal region, whereas patients demonstrated a significant increase in spontaneous activity. This post-exertional network hyperactivation provides a neurobiological correlate for cognitive exhaustion and post-exertional malaise. However, the study was limited by a small sample size, and it does not establish if this network dysfunction is specific to ME/CFS compared to other fatiguing illnesses. Sources:

2022-05-09 - Pathobiological case proposed for central neuroglial failure

A theoretical review proposed that a chronic, hyper-reactive state of brain support and immune cells—collectively termed neuroglia—could serve as a central pathway linking peripheral immune and vascular abnormalities to core clinical symptoms. The model suggests that primed microglia, astrocytes, and oligodendrocytes disrupt the regulation of cerebral blood flow through neurovascular coupling and impair baroreflex control, thereby explaining both reduced baseline perfusion and post-exertional cognitive relapses. By connecting metabolic, immune, and vascular dysfunction to a central CNS mechanism, this framework guides research toward therapies targeting the neuro-immune interface, such as minocycline, aripiprazole, and low-dose naltrexone. However, direct in vivo confirmation of widespread glial activation and blood-brain barrier disruption in patients remains incomplete. Sources:

2025-03-10 - Brain autopsies reveal hypothalamic alterations and altered microglial states

A post-mortem study analyzing brain tissue from the first ten donors of the Dutch ME/CFS Brain Bank, presented at the ZonMw Dutch ME/CFS Research Program meeting, identified specific structural and molecular changes in key regulatory brain regions rather than widespread chronic neuroinflammation. Histological and single-cell transcriptomic analyses revealed significant alterations in hypothalamic neurons responsible for producing corticotropin-releasing hormone (CRH) and vasopressin, alongside altered microglial activation states and mitochondrial protein signatures. These findings provide a cellular and neuroendocrine basis for the HPA-axis dysfunction and autonomic symptoms characteristic of the disease. However, the small initial sample size of ten cases and the complexity of interpreting post-mortem tissue in chronic, long-term illness limit the immediate generalizability of these findings. Sources:

2025-03-13 - Positron emission tomography indicates cholinergic receptor blockade in Long COVID

An imaging study using (-)-[18F]Flubatine PET-CT/MRI, presented at the Bioelectronic Medicine forum, demonstrated that the SARS-CoV-2 spike protein has a high affinity for nicotinic acetylcholine receptors (nAChRs), causing a functional blockade of cholinergic neurotransmission. A clinical case study showed that the administration of nicotine patches displaced the blocking viral proteins, resulting in the recovery of receptor availability and rapid clinical improvement in neurological and respiratory symptoms. This provides the first direct imaging evidence supporting the cholinergic hypothesis of post-viral cognitive symptoms, suggesting a targetable mechanism of receptor poisoning. However, the findings are limited to a case report and literature review, necessitating large-scale randomized trials to standardize therapeutic protocols and confirm efficacy. Sources:

2025-07-15 - Factor analysis identifies sensory overload as a distinct neurocognitive domain

A statistical analysis of self-reported symptoms from 2,313 ME/CFS patients and 299 Long COVID patients established that post-viral neurocognitive symptoms are structured into two distinct domains. The first domain comprises classic cognitive deficits such as memory loss, attention difficulties, and processing speed reduction, while the second comprises sensory and perceptual disturbances, including hypersensitivity to light, noise, and odors. This distinction suggests that cognitive complaints and sensory overload may be driven by separate neural substrates, potentially relating to the Central Executive Network and the Salience Network respectively. However, the study relied on self-reported surveys rather than objective cognitive testing, and clinical confirmation of these network associations is still required. Sources:

2025-08-08 - Plasma FGF-21 levels associate with distinct clinical and cognitive subgroups

A cross-sectional study of 250 patients and 54 healthy controls demonstrated that circulating levels of Fibroblast Growth Factor 21 (FGF-21), a hormone linked to mitochondrial stress, are elevated in ME/CFS and Long COVID but not in fibromyalgia alone. Patient stratification by hormone level revealed distinct profiles: low FGF-21 levels correlated with more severe post-exertional malaise and autonomic symptoms, whereas high FGF-21 levels correlated with better cognitive performance in the ME-only group but worse physical fatigue in the comorbid ME and fibromyalgia group. This highlights the utility of metabolic hormones for biological patient stratification, suggesting distinct therapeutic strategies for low-FGF-21 states (e.g., metformin or FGF-21 analogues) and high-FGF-21 hormone-resistant states. However, the cross-sectional design cannot establish causality, and longitudinal studies are required to track hormone stability over time. Sources:

2025-08-19 - Integrative model links peripheral pathology to central sickness circuits

A review proposed an integrative neuroinflammatory model wherein diverse peripheral abnormalities—such as viral persistence, gut dysbiosis, mitochondrial dysfunction, and autoantibodies—converge on the central nervous system. This peripheral inflammation is hypothesized to stimulate neural circuits in the brainstem and hypothalamus, activating evolutionarily conserved “sickness behavior” and “torpor-like” hypometabolic pathways that manifest as profound fatigue and cognitive deficits. The persistence of the illness is explained by interlocking, self-sustaining loops of pathology that reinforce one another. This model suggests that therapeutics targeting the central drivers of neuroinflammation may be more effective than addressing individual peripheral symptoms. However, the model is a theoretical synthesis, and direct clinical trials targeting these specific brainstem and hypothalamic circuits are needed to validate the pathway. Sources:

2025-08-28 - Haptoglobin phenotypes modulate post-exertional malaise and cognitive symptoms

A longitudinal study of 140 patients and 44 controls demonstrated that haptoglobin (Hp) levels significantly decrease in patients following a standardized stress test designed to induce post-exertional malaise, suggesting an exertion-triggered hemolysis and oxidative stress response. The study identified a genetic association where the less efficient Hp2-1 phenotype was linked to severe post-exertional malaise and cognitive deficits, whereas the Hp1-1 phenotype was associated with milder symptoms. This provides a molecular and genetic explanation for why post-exertional severity varies among patients, establishing haptoglobin structure as a candidate biomarker for patient stratification. However, the cohort included a small number of Hp1-1 patients, and phenotype-targeted interventions, such as administering protective Hp1-1, require clinical trial validation. Sources:

2025-09-23 - Longitudinal MRI shows structural compensation and brainstem stabilization over three years

A three-year longitudinal study tracking 51 Long COVID patients and 23 controls revealed slow but positive clinical improvement accompanied by brain structural reorganization and functional compensation. High-resolution MRI showed progressive volume loss in the thalamus and basal ganglia alongside increased regional neuronal activation, while early brainstem volume loss stabilized and showed enhanced functional connectivity. Importantly, blood biomarkers of neuronal damage (NfL, GFAP) and systemic inflammation remained normal, suggesting these brain changes represent cellular adaptation and compensation rather than progressive neurodegeneration. However, the study lacked an asymptomatic post-COVID control group, and the long-term clinical significance of persistent structural volume loss requires further study. Sources:

2025-10-01 - Study identifies systemic increase of brain AMPA receptors in Long COVID cognitive impairment

In a molecular imaging study published in Brain Communications, Fujimoto et al. used the novel AMPA receptor (AMPAR) PET tracer [11C]K-2 and structural MRI to study 30 patients with Long COVID-related cognitive impairment and 80 healthy controls. The researchers discovered a widespread, systemic increase in postsynaptic AMPAR density across large brain regions in patients. The level of AMPAR upregulation correlated with poorer cognitive performance on RBANS subscales (specifically Picture Naming and Figure Recall) and with plasma neuroinflammatory cytokines. A classification model using the AMPAR density data achieved 100% sensitivity and 91.25% specificity (AUC = 0.980) in distinguishing patients from controls. The study suggests that synaptic AMPAR upregulation drives cognitive dysfunction and poses a risk of excitotoxic neuronal damage. Limitations include a Japanese-only cohort, cross-sectional design, and small sample size.

Sources:

2025-11-25 - Multimodal MRI identifies persistent microstructural and neurochemical changes

A multimodal 3T MRI study evaluating 19 Long COVID patients, 12 recovered individuals, and 16 healthy controls found persistent myelin and microstructural changes in both the symptomatic and recovered groups compared to uninfected controls. Analysis of T1w/T2w mapping (indicating myelin integrity) and diffusion-weighted imaging (DWI) microstructural markers correlated significantly with clinical measures of physical and cognitive function. Furthermore, magnetic resonance spectroscopy (MRS) revealed unique neurochemical alterations restricted to the Long COVID cohort. This suggests that SARS-CoV-2 infection leaves a lasting microstructural imprint on the brain even in individuals who report full recovery. However, the small sample size limits the generalizability of these neurochemical findings, and longitudinal research is needed to determine if these changes are permanent. Sources:

2025-11-27 - Glymphatic system dysregulation proposed as waste clearance bottleneck

A literature review and theoretical analysis proposed that dysregulation of the glymphatic system, the brain’s sleep-active waste clearance pathway, is a central driver of cognitive dysfunction and sleep disturbances in ME/CFS. The authors suggest that impaired cerebral blood flow, neuroinflammation, and potential autoantibodies targeting aquaporin-4 (AQP4) water channels prevent the effective drainage of metabolic byproducts like lactic acid. This clearance failure is hypothesized to form a self-sustaining cycle where accumulated toxins disrupt sleep architecture, which in turn further impairs glymphatic flow. While offering a unified model for multi-system symptoms, direct neuroimaging of glymphatic flow in ME/CFS patients is still in its infancy, and the presence of AQP4-targeting autoantibodies remains to be verified. Sources:

2025-12-21 - Progressive neurophysiological dysfunction accumulates in persistent post-COVID fatigue

A cross-sectional study of 145 patients evaluated between 12 weeks and 45 months post-infection demonstrated that physiological abnormalities in the brain and muscles accumulate over time in patients who do not recover. Using transcranial magnetic stimulation (TMS) and reaction time tests, the researchers found that patients with fatigue persisting longer than 200 days exhibited significantly higher fatigue scores, increased cortical excitability, slower reaction times, and worse muscle fatigue than those with shorter durations. This suggests that post-viral fatigue involves a progressive decline in central and peripheral neurophysiological function rather than a static injury. However, the cross-sectional design limits the ability to establish individual trajectories, and longitudinal confirmation of this progressive decline is required. Sources:

2025-12-29 - Inappropriately low vasopressin secretion mimics central diabetes insipidus

An observational study of 111 ME/CFS patients who underwent a 10-hour fluid deprivation test demonstrated that 82% of patients had plasma vasopressin levels below the limit of detection, despite elevated blood osmolality that would normally trigger hormone release. The absence of structural pituitary or hypothalamic lesions on brain MRIs suggests a functional down-regulation of vasopressin-producing neurons. This chronic deficiency underpins hypovolemia, excessive thirst, frequent urination, and orthostatic intolerance, indicating central endocrine dysregulation of fluid homeostasis. However, the underlying cause of this functional neuronal shut-down remains unknown, and trials of vasopressin analogues are needed to determine if replacement therapy improves cardiovascular stability. Sources:

2026-01-10 - 31P MRS reveals bioenergetic energy depletion in the cingulate cortex

An in vivo 31P magnetic resonance spectroscopic imaging (31P-MRSI) study compared 27 Post-COVID patients with 23 recovered controls, showing significantly reduced ATP-to-phosphocreatine (ATP/PCr) ratios throughout the anterior, mid, and posterior cingulate cortex. Lower energy ratios in the anterior cingulate cortex correlated directly with poorer scores on cognitive performance tests. A subgroup analysis confirmed that patients meeting the diagnostic criteria for ME/CFS displayed the same bioenergetic impairments. This provides direct evidence of compromised brain energy metabolism and mitochondrial dysfunction in post-viral cognitive impairment. However, the study’s cross-sectional design cannot establish whether this metabolic deficit is the cause or consequence of chronic neuroinflammation. Sources:

2026-01-20 - High-resolution 7 Tesla fMRI maps distinct cognitive fatigue connectivity patterns

A task-fMRI study utilizing 7 Tesla imaging compared 78 participants (32 ME/CFS, 19 Long COVID, 27 controls) during a Stroop task to observe changes in brain network coordination during cognitive fatigue. While healthy controls showed increased communication between brain regions during fatigue, patients displayed reduced or dysregulated coordination. Long COVID patients exhibited significantly reduced functional connectivity within dopaminergic motivation and cognitive pathways (between the nucleus accumbens and vermis), whereas ME/CFS patients showed increased connectivity within subcortical brainstem regions (between the cuneiform nucleus and medulla). These distinct signatures suggest that despite overlapping clinical symptoms, the underlying neurobiological pathways driving cognitive fatigue may differ. However, the clinical utility of these patterns for individual diagnosis and tracking remains to be validated. Sources:

2026-01-28 - Theoretical model links symptoms to excitatory-inhibitory neurotransmitter imbalance

A neurobiological review proposed that a fundamental shift toward excitatory neurotransmission (glutamate, noradrenaline) over inhibitory signaling (GABA, serotonin) drives the “wired but tired” state, sensory hypersensitivity, and muscle dysfunction in ME/CFS. This imbalance is hypothesized to promote central brain overactivation and, in the periphery, lead to skeletal muscle hyperexcitability, calcium overload, and mitochondrial dysfunction. The framework suggests that restoring neurotransmitter equilibrium using agents like low-dose naltrexone, pyridostigmine, dextromethorphan, or memantine represents a logical therapeutic approach. However, direct measurement of these neurotransmitter levels in the brains and muscles of patients is limited, and high inter-individual variability remains a challenge for standardized treatment. Sources:

2026-02-10 - Task-fNIRS identifies rigid prefrontal capillary blood flow dynamics

A study monitoring prefrontal cortex blood flow using functional near-infrared spectroscopy (fNIRS) during cognitive tasks showed that patients with Post-COVID Syndrome have altered capillary regulation. Compared to healthy and coronary artery disease controls, patients exhibited significantly reduced temporal variability (rigid blood flow over time) but increased spatial variability in blood flow patterns during Flanker and N-back tests. These perfusion abnormalities correlated with slower reaction times, lower accuracy, and increased subjective fatigue. This indicates a physical impairment in neurovascular coupling and microvascular regulation during cognitive load. However, the study evaluated a small cohort, and validation in ME/CFS groups is required to confirm if this rigid prefrontal flow is a shared post-viral marker. Sources:

2026-02-10 - MRI reveals choroid plexus swelling and reduced perfusion associated with memory deficits

A neuroimaging study of 86 Long COVID patients, 67 recovered controls, and 26 healthy individuals demonstrated that symptomatic patients have a 10% larger choroid plexus volume and reduced blood flow compared to recovered controls. These alterations in the brain’s primary immune-regulating and CSF-producing structure correlated significantly with elevated plasma neurodegenerative markers (p-tau217) and worse cognitive scores. The study suggests that chronic immune responses cause swelling and vascular dysfunction in the choroid plexus, potentially hindering waste clearance and compromising the blood-CSF barrier. However, the cross-sectional design cannot confirm if these changes represent a permanent risk factor for neurodegeneration. Sources:

2026-03-13 - Post-exertional malaise mapped to a metabolism-immune-neuro interaction loop

An integrative review proposed a multi-system model for post-exertional malaise, describing an “energy exhaustion-inflammation amplification” loop. The model suggests that physical or cognitive exertion in patients triggers mitochondrial energy depletion and reactive oxygen species accumulation in skeletal muscle. These metabolic stressors activate the NLRP3 inflammasome, triggering a peripheral cytokine cascade that crosses the blood-brain barrier. The resulting neuroinflammation is hypothesized to alter neural processing in the insular cortex, amplifying the central perception of fatigue and pain and explaining delayed recovery. While providing a cohesive framework, clinical trials targeting both metabolic and neuroinflammatory pathways simultaneously are required to test the model’s therapeutic utility. Sources:

2026-03-16 - Advanced diffusion MRI detects widespread white matter neuroinflammation

A neuroimaging study of 67 patients and 67 matched controls using an advanced Neuroinflammation Imaging (NII) diffusion model identified widespread white matter abnormalities in patients, characterized by signs of cerebral edema, cellular infiltration, and axonal reorganization. While conventional Diffusion Tensor Imaging (DTI) failed to show significant differences or clinical correlations, lower levels of specific NII markers (such as hindered water ratio and restricted fraction) were associated with worse mental health scores and higher functional disability. This demonstrates that advanced diffusion models are highly sensitive to sub-clinical neuroinflammation in ME/CFS. However, these markers require longitudinal validation in independent cohorts to confirm their utility as diagnostic tools. Sources:

2026-04-03 - Cerebrospinal fluid proteomics identify severity and autonomic sub-phenotypes

A proteomic study analyzing cerebrospinal fluid from 31 patients identified distinct protein signatures and biological pathways associated with clinical severity and the presence of postural orthostatic tachycardia syndrome (POTS). Patients with comorbid POTS showed significant enrichment in neutrophil degranulation and platelet activation pathways, alongside marked upregulation of synaptic growth protein GAP43. Severe cases exhibited enrichment of the complement cascade and insulin-like growth factor transport. Additionally, four specific protein ratios representing cellular stress and extracellular remodeling correlated significantly with clinician-defined disease severity. However, the study lacked a healthy control group due to ethical restrictions on lumbar punctures, limiting the specificity of these markers. Sources:

2026-04-20 - Cell-resolved model maps the immune-vascular-cognitive axis in brain fog

A review synthesized neuroimaging and neurobiological evidence to outline an “immune-vascular-cognitive axis” explaining how systemic inflammation causes cognitive impairment. The framework maps dynamic interactions within the neurovascular unit, showing that microglial priming and astrocytic dysfunction disrupt synaptic homeostatic mechanisms and create an excitation-inhibition imbalance. Crucially, the model suggests that cognitive dysfunction in ME/CFS reflects a state of persistent neuroimmune and neurometabolic dysregulation rather than permanent structural damage, indicating that the cognitive decline is potentially reversible. Proposed targets for therapeutic validation include cytokine blockades, nitric oxide enhancement, and acupuncture to restore neurovascular health. However, direct causal validation of these cellular interactions in human patients remains a challenge. Sources:

2026-04-23 - Meta-analysis establishes a hyporeactive neuroendocrine and cortisol signature

A large-scale meta-analysis of 46 case-control studies involving 1,388 patients and 1,349 controls identified a definitive hyporeactive neuroendocrine profile in ME/CFS. Patients exhibited significantly lower cortisol levels in saliva (upon awakening and in the morning), 24-hour urine, and hair compared to controls. Additionally, patients showed a blunted cortisol response to ACTH stimulation and an exaggerated sensitivity to glucocorticoid suppression, indicating a chronically underactive endocrine stress-response system. This underactive HPA axis likely contributes to unrefreshing sleep, fatigue, and cognitive slowing. However, the clinical efficacy of low-dose hydrocortisone replacement therapy to correct this deficit remains to be established in large randomized controlled trials. Sources:

2026-04-24 - Ultra-high-field 7T MRS detects visual task-induced cerebral lactate accumulation

A metabolic imaging study using 7 Tesla functional magnetic resonance spectroscopy (fMRS) compared 20 ME/CFS patients and 20 controls during visual stimulation with a flashing checkerboard. While baseline lactate levels did not differ between the groups, visual stimulation triggered a 22.2% increase in lactate in the visual cortex of patients, compared to only a 10.6% increase in healthy controls, with other metabolites remaining stable. This provides in vivo evidence that visual processing forces the brain into inefficient anaerobic metabolism under load, representing a metabolic bottleneck in energy production. However, further studies are needed to determine if these visual cortex lactate levels correlate with post-exertional symptom flares. Sources:

2026-04-28 - Endothelial activation markers correlate with cognitive deficits and resolve late-stage

A study evaluating 50 Long COVID patients at one year and 114 patients at three years post-infection linked cognitive deficits to ongoing blood vessel inflammation and endothelial activation. One-year patients showed significantly elevated plasma markers of leukocyte and platelet adhesion (including sL-selectin, ADAMTS13, sP-selectin, and sICAM-1) compared to controls, with sP-selectin correlating with poorer verbal fluency and memory. Interestingly, these differences were absent in the late-stage cohort (nearly three years post-infection), suggesting that vascular-driven inflammation may resolve or transition into a different chronic phase over time. However, the study’s cross-sectional design cannot establish causality, and longitudinal follow-up is required to confirm the trajectory of endothelial recovery. Sources:

2026-05-07 - Conference presentation highlights gut-brain-immune axis metabolites and brainstem serotonin regulation

At the Internationale ME/CFS-Konferenz 2026 in Berlin, Dr. Helena Radbruch presented SERIMM consortium findings linking cognitive and autonomic symptoms to dysregulation of the gut-brain-immune axis. The research demonstrated that Post-COVID patients exhibit elevated levels of the gut metabolite trimethylamine N-oxide (TMAO) and kynurenine pathway activation, patterns similar to inflammatory disease controls like multiple sclerosis. In contrast, serotonin levels in the cerebrospinal fluid were not reduced, although the peripheral serotonin-to-tryptophan ratio was decreased. Spatial sequencing of brainstem tissue suggested that endothelial cells, rather than neurons, are the primary site of serotonin-metabolizing enzyme expression. These findings highlight that neurocognitive symptoms are driven by complex metabolic and endothelial pathways rather than a simple central serotonin deficiency, though translating these animal and tissue-level models to live patient clinical outcomes remains a key challenge. Sources:

2026-05-13 - Systems model links connective tissue degradation to chronic inflammatory loops

A theoretical model proposed a bidirectional cycle where preexisting ligament laxity predisposes individuals to orthostatic stress and ME/CFS, while ME/CFS-associated pathophysiological processes further degrade connective tissues. The hypothesis suggests that chronic mast cell activation releases enzymes (tryptase and chymase) that activate collagen-degrading metalloproteinases. Simultaneously, local tissue hypoxia and oxidative stress inhibit prolyl hydroxylases (PHDs), impairing collagen stability and leading to basement membrane thickening and reduced capillary density. In the neck, this metabolic muscle dysfunction impairs the ability to compensate for lax ligaments, worsening craniocervical instability. While providing a molecular explanation for the high rates of hypermobility and POTS comorbidity, direct measurement of these enzyme and collagen pathways in clinical cohorts is required. Sources:

2026-06-01 - Study links central sensitization in Long COVID to neuroinflammation and cerebral hypoperfusion

A prospective study of 169 Long COVID patients with orthostatic intolerance published in the Journal of the Neurological Sciences by Novak and Iyer showed that 81% met criteria for central sensitization (CS) using the Central Sensitization Inventory (CSI). Patients with CS had a significantly higher burden of headaches, fibromyalgia, anxiety, depression, and autonomic symptoms, and were more likely to be female. Physically, the CS group demonstrated a greater decrease in orthostatic cerebral blood flow velocity (-25.5% vs. -22.1%) and significantly higher levels of Interleukin-6 (IL-6) compared to the non-CS group. The rate of objective autonomic failure was similar between groups, suggesting central sensitization amplifies symptom burden and interacts with neuroinflammation and cerebral hypoperfusion rather than autonomic structural damage. Limitations include referral bias for orthostatic intolerance, subjective nature of the CSI, and cross-sectional associations.

Sources:

2026-06-02 - DTI study reveals subacute frontoinsular-cingulate tract changes in unvaccinated hospitalized COVID-19 survivors

A prospective, observational case-control study by Christophe T. Arendt and colleagues from Goethe University Frankfurt (published in Brain Research Bulletin) utilized diffusion tensor imaging (DTI) and quantitative T1 mapping (qT1) to evaluate 145 unvaccinated subjects (69 COVID-19 survivors, 76 seronegative controls). While no significant cohort-wide DTI differences were found, a subgroup of 23 hospitalized survivors aged ≥40 years exhibited significant right-sided microstructural white matter alterations—including decreased fractional anisotropy (FA) and increased radial diffusivity (RD)—in the frontoinsular-cingulate pathway (salience network). These microstructural changes correlated with elevated fatigue, depressive symptoms, and sleep disturbances, suggesting reduced fiber integrity and persistent oxidative stress. Limitations include a small subgroup sample size (n=23) and lack of pre-infection baseline neuroimaging data.

Sources:

2026-06-03 - Multimodal MRI protocol launched to investigate acupuncture mechanisms in post-COVID cognitive dysfunction

A randomized controlled trial protocol (NCT07357688) was published to evaluate the clinical efficacy and underlying neurological mechanisms of acupuncture for cognitive impairment in post-COVID-19 ME/CFS. Enrolling 129 patients and 30 healthy controls, the study randomizes patients to verum acupuncture, sham acupuncture (non-acupoint stimulation), or waitlist control (43 per group). The researchers plan to use multimodal MRI—specifically resting-state functional connectivity and metabolic MRI—to measure structural and metabolic changes in the hippocampus. While this study represents a rigorous attempt to evaluate acupuncture’s potential to restore neurovascular or network health, the publication provides only the trial design. Blinding remains an inherent challenge in acupuncture trials, and clinical efficacy remains to be proven when the trial is completed. Sources:

2026-06-09 - Systematic review maps widespread structural brain alterations correlating with cognitive dysfunction

A systematic review and meta-synthesis of 12 neuroimaging studies including 652 participants (428 ME/CFS patients and 224 controls) confirmed objective alterations in brain structure and connectivity. The analysis showed that 42% of the studies reported white matter alterations (such as decreased connectivity), 16% reported grey matter volume reductions, and 42% reported changes in both. The most frequently affected regions were the precentral gyrus (66%), prefrontal cortex (58%), and subcortical basal ganglia and thalamus (42% each), areas critical for motor control and executive function. Although these widespread alterations correlate with clinical fatigue and brain fog, the review is limited by the methodological heterogeneity and small sample sizes of the primary studies, which often relied on the older Fukuda diagnostic criteria. Sources:

2026-06-18 - Preliminary MELOPIS study results show astrocyte activation and default mode network inefficiency

In a study update for the MELOPIS project (supported by Open Medicine Foundation Australia), Dr. Chris Armstrong and Jamie Elliott reported preliminary multimodal imaging findings in ME/CFS patients. Using a novel PET tracer that targets activated astrocytes, they observed chronic astrocyte activation concentrated in the default mode network (DMN), providing a potential mechanistic reason for the DMN dysfunction and difficulty switching out of resting states. Additionally, task fMRI showed that patients activate wider, less directed brain regions and expend more metabolic energy than healthy controls to perform the same task, reflecting cellular adaptation and energetic inefficiency. The study involves two visits for 7T MRI and PET scans at the Melbourne Brain Centre. As a study update presentation, these findings are preliminary and subject to completion and peer-reviewed publication of the full trial.

Sources:

2026-06-19 - Conference review outlines localized subcortical volume loss, hypoperfusion, and metabolic alterations

Prof. Dr. Carsten Finke presented a comprehensive summary of neuroimaging findings in ME/CFS and post-COVID syndrome at the International ME/CFS Conference 2026 in Berlin. The presentation detailed structural MRI evidence of localized volume reductions in the thalamus and pallidum, alongside diffusion tensor imaging (DTI) white matter changes that correlate with physical fatigue. Functional resting-state MRI showed reduced connectivity within default mode network (DMN), hippocampal, and thalamic circuits, while arterial spin labeling (ASL) documented regional cerebral hypoperfusion correlating with symptom severity. Additionally, 7-Tesla MR spectroscopy (MRS) revealed metabolic abnormalities (elevated lactate and glutamate, reduced choline) indicating impaired energy metabolism. A pilot study of 30 patients also suggested that hyperbaric oxygen therapy (HBOT) might normalize elevated thalamic connectivity, though these preliminary findings are based on small cohorts and require large-scale, peer-reviewed replication before clinical adoption. Sources:

2026-06-19 - First study demonstrating glymphatic dysfunction in ME/CFS linked to sleep and cognitive symptoms

In a study published in Frontiers in Neuroscience, Kiran Thapaliya and colleagues at Griffith University’s National Centre for Neuroimmunology and Emerging Diseases (NCNED) demonstrated for the first time impaired glymphatic (brain waste clearance) function in patients with ME/CFS. Using 3T MRI to calculate the DTI-ALPS index in 58 participants (31 ME/CFS, 27 healthy controls), they found that the global DTI-ALPS index was significantly lower in ME/CFS patients compared to controls. This reduction was driven by the right hemisphere. Furthermore, lower glymphatic clearance strongly correlated with greater severity of sleep disturbance and impaired concentration, suggesting that the accumulation of toxic metabolic waste in the brain due to glymphatic clearance failure may drive neuroinflammation and corresponding clinical symptoms. Limitations include a cross-sectional design, modest sample size, and unmeasured variables like sleeping position.

Sources:

2026-06-20 - Comprehensive review proposes chronobiology-aware neuroendocrine framework for ME/CFS and Long COVID research

Thomas, Armstrong, and colleagues published a systems-level review in Frontiers in Neuroendocrinology proposing a chronobiology-aware framework for studying neuroendocrine disruption in ME/CFS and Long COVID. The authors argue that hormonal findings have often been studied in isolation without accounting for circadian and menstrual rhythms. The review examines evidence for hypothalamic-pituitary-adrenal/gonadal axis dysfunction across immune, autonomic, nervous, and metabolic systems, and identifies sex hormone signaling as a key area of vulnerability. They propose a chronobiology-aware research framework combining dense time-point sampling (mapping diurnal and menstrual phase), multi-omic integration, and multi-system study designs to detect meaningful endocrine differences and support personalized interventions. As a review, this paper synthesizes literature and does not generate new primary data.

Sources:

2026-06-23 - Multimodal imaging and literature review characterize neuroinflammatory connectivity and multi-system pathology in Long COVID

A multimodal neuroimaging study combining [18F]DPA-714 PET and resting-state fMRI in 45 post-COVID syndrome (PCS) patients demonstrated that the 22% of patients with high neuroinflammatory activity had decreased functional connectivity in cognitive networks, particularly the visual-peripheral and dorsal-attention networks. A significant correlation was observed between increasing neuroinflammation and reduced connectivity in the cerebellum. Concurrently, a comprehensive literature review in the Journal of Neuroimmunology synthesized these findings with wider systemic pathways, mapping how neuroinflammation, blood-brain barrier disruption, endothelial activation, hypoperfusion, and autoantibodies interact to drive neuropsychiatric symptoms. While these studies reinforce the biological reality of post-viral brain fog, both emphasize key caveats: the PET tracer requires complex TSPO genotyping that limits scalability, and the precise causal relationships among these multi-system mechanisms remain to be established in prospective, longitudinal trials. Sources:

2026-06-28 - Study finds persistent cerebral hypometabolism in Long COVID patients with fatigue and PEM

In a retrospective study published in the Journal of Primary Care & Community Health, Dr. Ravindra Ganesh and colleagues at the Mayo Clinic evaluated brain metabolic activity using 18F-FDG PET-CT scans in 40 patients with Long COVID. Compared to a normative database, they identified significant, persistent cerebral hypometabolism in the 29 patients presenting with fatigue and post-exertional malaise (PEM). The hypometabolism was most pronounced in the left sensorimotor cortex and bilateral primary visual cortex, persisting up to two years post-infection. These findings provide objective evidence of long-term central nervous system metabolic alterations in a phenotype of Long COVID that overlaps significantly with ME/CFS. Limitations include a small sample size, demographically homogeneous cohort, retrospective design, lack of a prospective matched control group, and no correction for multiple statistical testing.

Sources:

2026-06-29 - Comparative DTI/DKI imaging reveals shared yet distinct white matter microstructural changes

A comparative neuroimaging study combining Diffusion Tensor Imaging (DTI) and Diffusion Kurtosis Imaging (DKI) in 37 ME/CFS patients, 19 Long COVID patients, and 27 controls mapped distinct white matter microstructural alterations. ME/CFS patients exhibited microstructural changes in the cingulum, supplementary motor areas, and corpus callosum, whereas Long COVID patients showed alterations in the fusiform gyrus, precentral gyrus, and major white matter tracts. A direct comparison between the two patient cohorts identified a significant difference in the left corona radiata, illustrating unique pathological signatures despite overlapping clinical profiles. These findings provide objective evidence of microstructural tissue changes that may underlie cognitive and motor fatigue, though the study’s cross-sectional design cannot determine if these changes are progressive or reversible over time. Sources:

2026-07-10 - Electrophysiological and cell-resolved models frame cognitive dysfunction as higher-order, reversible neural dysregulation

An event-related potential (ERP) study by Kumar et al. evaluating 31 ME/CFS patients and 30 controls demonstrated that sensory hypersensitivity is mediated by higher-order cognitive control systems rather than early sensory gating deficits. Patients showed intact early auditory P50 suppression but a significantly reduced late P300 potential, indicating that deficits in stimulus evaluation and working memory updating underlie sensory overload. Complementing this, a comprehensive review proposed a cell-resolved framework for cognitive dysfunction, integrating microglial priming, astrocytic dysfunction, prefrontal-hippocampal excitation-inhibition (E/I) imbalance, and neurovascular unit breakdown. The review argues that “brain fog” represents a functional, potentially reversible neurometabolic and neuroimmune state rather than structural neurodegeneration. While these models offer a cohesive biological explanation for sensory and cognitive symptoms, they rely on cross-sectional data, and direct clinical trials targeting these specific cellular and higher-order networks are needed to confirm reversibility. Sources:

2026-07-12 - PET imaging reveals striatal dopamine system injury in Long COVID

A PET imaging study evaluated vesicular monoamine transporter 2 (VMAT2) binding—an index of dopamine terminal density—in patients with Long COVID compared to healthy controls. The researchers identified significantly lower VMAT2 levels in the striatum of the Long COVID cohort. Localized VMAT2 reductions in the ventral striatum correlated with decreased motivation, while reductions in the dorsal putamen and caudate/putamen linked to slowed motor performance and memory deficits, respectively. However, cohort sizes and statistical metrics are not detailed in the available summary, and further validation is needed to determine the clinical utility of targeting the dopamine system. Sources:

2026-07-16 - Post-COVID fatigue associated with peripheral immunometabolic changes affecting hippocampal function

A study of 38 individuals with past COVID-19 infection showed that fatigue severity correlates with lower serum levels of interleukin-8 (IL-8), tryptophan-derived and monoamine-related metabolites (such as 5-hydroxyindoleacetic acid [5HIAA]), and kynurenine pathway metabolites (kynurenine and quinolinic acid). To investigate central effects, the researchers exposed human hippocampal progenitor cells to 1% patient serum in vitro. However, the study is limited by a small cohort size, and in vitro models using diluted serum may not fully represent the complex, in vivo neuroimmune microenvironment of the human hippocampus. Sources:

2026-07-19 - Cerebrospinal fluid opening pressure and craniocervical anatomy evaluated in ME/CFS

A case-control study of 34 patients with ME/CFS (65% of whom had moderate disease severity) investigated cerebrospinal fluid (CSF) opening pressure, clinical symptoms, and craniocervical anatomy. Lumbar punctures were performed to measure opening pressure—utilizing a 20 cmH2O cut point for patient stratification—and evaluate symptomatic relief post-procedure. However, this study is limited by a small cohort size and the lack of healthy controls undergoing lumbar punctures, and specific statistical outcomes or radiological correlations were not fully detailed in the available summary. Sources:

2026-07-21 - Expert review synthesizes neuroinflammatory mechanisms and biomarker targets in post-COVID-19 syndrome

An expert review published in Translational Psychiatry by Martins and colleagues synthesized central nervous system alterations following SARS-CoV-2 infection, including microglial activation, astrogliosis, and neurovascular unit disruption. The authors evaluated TSPO PET neuroimaging and advanced diffusion MRI techniques as validated tools to quantify central neuroinflammation, alongside fluid biomarker candidates such as NfL, GFAP, and proinflammatory cytokines for patient stratification. The paper outlines targetable neuroimmune pathways for microglial modulation and neurovascular repair in post-viral brain fog. However, as an expert narrative review, it provides conceptual synthesis rather than novel empirical clinical cohort data. Furthermore, extrapolation of post-COVID-19 neuroinflammatory pathways to classic post-infectious ME/CFS requires explicit translational validation in prospective cohorts.

Sources:

2026-07-25 - Preclinical study demonstrates CCL5-dependent microglial activation driving central neuroinflammation under hypoxia

A mechanistic study published in the Journal of Advanced Research by Guo et al. investigated how systemic peripheral inflammation exacerbates central nervous system inflammation under hypoxic stress. Using cellular and animal models, the researchers demonstrated that peripheral inflammatory signaling drives microglial activation and neuroinflammatory cytokine amplification specifically through a CCL5 chemokine-dependent signaling axis. This elucidates a key biological pathway explaining how peripheral inflammatory triggers, such as post-viral flares, translate into central neuroinflammation and cognitive exhaustion. However, the study relies on preclinical models, and translational validation in human clinical ME/CFS or Long COVID cohorts is necessary before clinical applications can be derived.

Sources:

2026-07-26 - Medical review details CNS pathomechanisms and neuropsychiatric features of Long/Post-COVID syndrome

A comprehensive German medical review published in Thieme Connect eJournals synthesized the neuropsychiatric and neuroimmunological manifestations of Long/Post-COVID syndrome. The article details central nervous system pathways, neuroinflammation, microstructural brain changes, cognitive deficits, and differential diagnostic strategies for clinical management. It provides structured guidance for clinicians evaluating central nervous system and cognitive symptoms in post-viral patients. However, the publication represents a narrative clinical review summarizing existing literature rather than presenting novel empirical trial or cohort data. Additionally, it focuses on the European clinical practice context and German healthcare framework.

Sources:

2026-07-29 - Predictive processing model frames thalamocortical hyperconnectivity as reversible thalamic gain control failure

A theoretical commentary published in the Journal of Translational Medicine by Strube analyzed neuroimaging findings demonstrating baseline thalamocortical hyperconnectivity with sensorimotor and visual cortices in ME/CFS. The author highlighted that this thalamocortical hyperconnectivity shifts back toward healthy control levels following hyperbaric oxygen therapy (HBOT) in clinical responders. Based on these observations, the paper formulated a predictive processing model where thalamic gain-control failure drives sensory overload, pain, dysautonomia, and cognitive fatigue in post-infectious states. The framework proposes dynamic testing of thalamic gating across post-exertional malaise states rather than static resting-state imaging alone. However, resting-state functional connectivity provides an indirect measure of thalamic gain control, and prospective dynamic trials are required to validate the model’s predictive accuracy.

Sources:

2026-08-01 - Multimodal neuroimaging reveals central brain network dysfunction driving physical and cognitive fatigability

A multimodal neuroimaging study published in NeuroImage: Clinical utilized functional MRI and EEG during motor and cognitive fatigue tasks to identify central nervous system alterations driving early fatigability in ME/CFS. The researchers demonstrated a central nervous system failure to upregulate motor drive during fatiguing physical tasks in patients compared to healthy controls, revealing a functional disconnect between cortical/subcortical effort processing and peripheral motor output. This confirms a biological, central neural origin of physical and cognitive fatigability that is distinct from peripheral muscle fatigue or deconditioning. The findings provide objective neuroimaging evidence that exertional fatigue in ME/CFS stems from central brain network dysfunction. However, as a cross-sectional study, longitudinal tracking is required to determine whether these central network alterations resolve with clinical recovery.

Sources:

2026-08-12 - Multimodal MRI with controlled hypoxia finds blunted thalamic lactate response in ME/CFS

A proof-of-concept multimodal 3T MRI study posted on medRxiv by Bader and colleagues evaluated in vivo neurovascular and neurometabolic responses to experimental physiological stress in 26 patients with Canadian Consensus Criteria-defined ME/CFS and 27 matched healthy controls. Under baseline normoxia, structural volumetry revealed significantly reduced normalized brainstem volume, while multivoxel proton magnetic resonance spectroscopy (1H-MRS) demonstrated elevated thalamic lactate-to-creatine ratios in ME/CFS patients. Crucially, during controlled normobaric hypoxic challenges (SpO2 87 ± 3%), patients failed to mount the normal physiological compensatory increase in thalamic lactate seen in healthy controls, indicating an exhausted neurometabolic reserve accompanied by heightened cerebral blood flow variability on arterial spin labeling and exaggerated inverse coupling between thalamic total N-acetylaspartate and white-matter perfusion. These findings provide direct in vivo proof-of-concept evidence for the “virtual hypoxia” hypothesis, demonstrating that baseline metabolic strain and blunted adaptive reserve under physiological challenge connect central nervous system changes to mechanisms in Vascular Endothelial Dysfunction & Microclots and Mitochondrial & Metabolic Dysfunction. However, the study is an un-peer-reviewed preprint with a modest sample size that requires prospective multi-center replication, and the demanding in-scanner breathing protocol excluded severe and bedbound patients. Additionally, controlled normobaric hypoxia is a monitored research-only provocation tool carrying post-exertional symptom flare risks, not a diagnostic test or self-administrable intervention.

Sources:

Preclinical & Animal Studies

  • 2025-11-20 - Passive transfer of patient IgG induces sensory pain and binds peripheral neurons in mice A passive transfer study demonstrated that purified IgG antibodies from Long COVID patients with neurological symptoms cause a transient increase in mechanical pain sensitivity (allodynia) when injected into mice, whereas healthy control IgG does not. Fluorescent imaging revealed that the patient-derived antibodies accumulated in the lumbar dorsal root ganglia (DRG) and bound directly to sensory neurons, with no neuroinflammation detected in the brain. This establishes a direct, antibody-mediated cause for peripheral pain and sensory symptoms, pointing toward antibody-targeted treatments like plasma exchange or immune modulators. However, the passive transfer failed to replicate cognitive impairment, anxiety, or depression in the mice, suggesting that cognitive “brain fog” is driven by distinct, non-antibody mechanisms or requires chronic exposure. Sources:

  • 2026-04-08 - Nasal anti-CD3 treatment reverses neuroinflammation and restores neurogenesis in mice A preclinical study utilizing a mouse model of Long COVID demonstrated that intranasal administration of anti-CD3 monoclonal antibodies reduces chronic neuroinflammation and restores cognitive function. The treatment increased the recruitment of protective regulatory T cells (Tregs) to the brain and shifted primed microglia from a pro-inflammatory to a restorative, tissue-healing state. This immunomodulatory shift reduced brain inflammation, restored hippocampal neurogenesis, and improved short-term memory. The study also found that humans with neurological Long COVID have lower levels of the same protective Tregs. However, human clinical trials are required to determine if intranasal anti-CD3 therapies replicate these neuroprotective and cognitive recovery effects in patients. Sources:

Open Questions

  • What is the precise temporal sequence of events linking peripheral metabolic exhaustion (NLRP3 activation) to central neurovascular dysfunction during post-exertional malaise?
  • What are the molecular mechanisms by which specific haptoglobin structural variants (oligomers in the Hp2-1 phenotype) interact with brain vascular endothelium to promote cognitive fatigue?
  • What specific ligands target the hyporeactive hypothalamic CRH and vasopressin neurons, and can targeted neuroendocrine therapies restore long-term HPA axis homeostasis?
  • How does the elevated visual cortex lactate production observed under ultra-high-field 7T functional MRS correlate with structural myelin loss or neurochemical alterations in adjacent white matter?
  • By what mechanism does intranasal anti-CD3 monoclonal antibody treatment promote the recruitment of protective regulatory T cells to the brain, and can this reverse established glial priming in human cohorts?
  • Does targeted CCL5 chemokine inhibition or microglial modulation attenuate hypoxia-exacerbated central neuroinflammation in human post-viral cohorts?
  • How reliably does the normalization of thalamocortical hyperconnectivity observed after hyperbaric oxygen therapy correlate with long-term clinical recovery in ME/CFS?
  • Does blunted thalamic lactate elevation and altered neurovascular coupling under experimental hypoxia predict post-exertional malaise severity across clinical ME/CFS subgroups?

0 items under this folder.

    Graph View

    Backlinks